Clinical trial
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma…
NCT00339131 · Molecular Insight Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00339131 |
|---|---|
| Title | ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid |
| Official title | Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid |
| Lead sponsor | Molecular Insight Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pheochromocytoma, Paraganglioma, Carcinoid |
| Intervention type | Drug |
| Interventions | Ultratrace iobenguane I 131 |
| Enrollment | 24 |
| Start date | Jun 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | Jun 20, 2006 |
| Last update posted | Oct 12, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: